Michael Taylor

Michael Taylor

Auto-generated profile, based on publicly available information

Michael Taylor

Peter MacCallum Cancer Centre, Melbourne, Australia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
CDCatherine Dietrich
Catherine Dietrich
ATAlec Trub
Alec Trub
AAAntonio Ahn
Antonio Ahn
MTMichael Taylor
Michael Taylor
KAKrutika Ambani
Krutika Ambani
SGShom Goel
Shom Goel
Cyclin-dependent kinase 2 (CDK2) is thought to play an important role in driving proliferation of certain cancers, including those harboring CCNE1 amplification and breast cancers that have acquired resistance to CDK4/6 inhibitors (CDK4/6i). The precise impact of pharmacologic inhibition of CDK2 is not known due to the lack of selective CDK2 inhibitors. Here we describe INX-315, a novel and potent CDK2 inhibitor with high selectivity over other CDK family members. Using cell-based assays, patient-derived xenografts (PDX), and transgenic mouse models, we show that INX-315 (i) promotes retinoblastoma protein hypophosphorylation and therapy-induced senescence (TIS) in CCNE1-amplified tumors, leading to durable control of tumor growth; (ii) overcomes breast cancer resistance to CDK4/6i, restoring cell cycle control while reinstating the chromatin architecture of CDK4/6i-induced TIS; and (iii) delays the onset of CDK4/6i resistance in breast cancer by driving deeper suppression of E2F targets. Our results support the clinical development of selective CDK2 inhibitors. Significance: INX-315 is a novel, selective inhibitor of CDK2. Our preclinical studies demonstrate activity for INX-315 in both CCNE1-amplified cancers and CDK4/6i–resistant breast cancer. In each case, CDK2 inhibition induces cell cycle arrest and a phenotype resembling cellular senescence. Our data support the development of selective CDK2 inhibitors in clinical trials. See related commentary by Watts and Spencer, p. 386. This article is featured in Selected Articles from This Issue, p. 384

12 August 2026 in Nature
Verified
Journal Article
Open access
PDF file
AWApril C. Watt
April C. Watt
AAAntonio Ahn
Antonio Ahn
CBCatherine Blyth
Catherine Blyth
JDJulia R. Dixon-Douglas
Julia R. Dixon-Douglas
KAKrutika Ambani
Krutika Ambani
SGShom Goel
Shom Goel
The retinoblastoma protein (Rb) is a tumour suppressor best known for repressing E2F transcription factors and halting cell cycle progression 1 . In hormone receptor-positive (HR + ) breast cancer, CDK4/6 inhibitors activate Rb by preventing its phosphorylation, forming a key component of current endocrine therapy regimens 2 . How pharmacologically activated Rb remodels chromatin and influences transcription beyond cell cycle arrest remains poorly understood. Here we show that CDK4/6 inhibition induces redistribution of hypophosphorylated Rb to promoters and enhancers. Although Rb predictably binds to cell cycle gene promoters to repress transcription, at other sites, it unexpectedly promotes expression of oestrogen-responsive genes by integrating into oestrogen receptor (ER)-rich transcriptional hubs. CDK4/6 inhibition enhances ER target gene expression in breast cancer cells, patient-derived xenografts and clinical HR + breast cancer samples in an Rb-dependent manner. This reprogramming is mediated in part by KDM5A, whose interaction with Rb contributes to gene regulation at these loci. Critically, components of this Rb-driven ER transcriptional program are pro-proliferative. In endocrine-sensitive tumours, this effect can be neutralized with anti-oestrogen therapy, explaining therapeutic synergy. In endocrine-resistant settings such as ESR1 -mutant breast cancer, the program persists, limiting the therapeutic efficacy of CDK4/6 inhibition. These findings reframe Rb as a dual-function transcriptional regulator that, although enforcing cell cycle arrest, can also activate programs that counteract its tumour suppressor function.

1 June 2022 in The Journal of Cardiovascular Surgery
Verified
Journal Article
Closed access
RSReny Segal
Reny Segal
PMPaul M. Mezzavia
Paul M. Mezzavia
RKRoni B. Krieser
Roni B. Krieser
SSShienny Sampurno
Shienny Sampurno
MTMichael Taylor
Michael Taylor
INIrene Ng
Irene Ng
Article: Warm humidified CO2 insufflation improves pericardial integrity for cardiac surgery. A randomized control study - The Journal of Cardiovascular Surgery 2022 Mar 28 - Minerva Medica - Journals

1 March 2024
Verified
Other
Open access
CDCatherine Dietrich
Catherine Dietrich
ATAlec Trub
Alec Trub
AAAntonio Ahn
Antonio Ahn
MTMichael Taylor
Michael Taylor
KAKrutika Ambani
Krutika Ambani
SGShom Goel
Shom Goel
Cyclin-dependent kinase 2 (CDK2) is thought to play an important role in driving proliferation of certain cancers, including those harboring CCNE1 amplification and breast cancers that have acquired resistance to CDK4/6 inhibitors (CDK4/6i). The precise impact of pharmacologic inhibition of CDK2 is not known due to the lack of selective CDK2 inhibitors. Here we describe INX-315, a novel and potent CDK2 inhibitor with high selectivity over other CDK family members. Using cell-based assays, patient-derived xenografts (PDX), and transgenic mouse models, we show that INX-315 (i) promotes retinoblastoma protein hypophosphorylation and therapy-induced senescence (TIS) in CCNE1-amplified tumors, leading to durable control of tumor growth; (ii) overcomes breast cancer resistance to CDK4/6i, restoring cell cycle control while reinstating the chromatin architecture of CDK4/6i-induced TIS; and (iii) delays the onset of CDK4/6i resistance in breast cancer by driving deeper suppression of E2F targets. Our results support the clinical development of selective CDK2 inhibitors.Significance:INX-315 is a novel, selective inhibitor of CDK2. Our preclinical studies demonstrate activity for INX-315 in both CCNE1-amplified cancers and CDK4/6i–resistant breast cancer. In each case, CDK2 inhibition induces cell cycle arrest and a phenotype resembling cellular senescence. Our data support the development of selective CDK2 inhibitors in clinical trials.See related commentary by Watts and Spencer, p. 386.This article is featured in Selected Articles from This Issue, p. 384

1 March 2024
Verified
Other
Open access
PDF file
CDCatherine Dietrich
Catherine Dietrich
ATAlec Trub
Alec Trub
AAAntonio Ahn
Antonio Ahn
MTMichael Taylor
Michael Taylor
KAKrutika Ambani
Krutika Ambani
SGShom Goel
Shom Goel
Description of methods to synthesize INX-315

1 March 2024
Verified
Other
Open access
CDCatherine Dietrich
Catherine Dietrich
ATAlec Trub
Alec Trub
AAAntonio Ahn
Antonio Ahn
MTMichael Taylor
Michael Taylor
KAKrutika Ambani
Krutika Ambani
SGShom Goel
Shom Goel
Activity of INX-315 in CCNE1-amplified cancers. A, IC50s for palbociclib and INX-315 for cell lines shown using CellTiter Glo viability assay. All cells were treated for 6 days, n = 3 technical replicates per cell line. B, Cell cycle phase profiles of OVCAR-3 and MKN1 cells treated with INX-315. All cells were treated for 24 hours, n = 3 technical replicates per cell line; error bars are SD. C, Western blots for phosphorylated/total Rb and cyclin A2 in OVCAR3 and MKN1 cells treated with INX-315 for 24 hours. D and E, Tumor growth curves for CCNE1-amplified gastric and ovarian carcinoma models treated with INX-315 at doses shown (GA0103 n = 8 per group; GA0114 n = 8 per group; OVCAR3 n = 10 per group; OV5398 n = 10 per group; error bars represent SEM; P values calculated using two-way ANOVA. all experiments performed once). F, Western blots for phosphorylated/total Rb and cyclin A2 in tumor tissue lysates treated with control vehicle or INX-315. Samples were collected at experimental endpoint from experiments in E.